Table 3. Mean cost, effectiveness and cost-effectiveness results with 95% uncertainty ranges.
| Parameter | EES (n = 751) | BMS (n = 747) | Δ (EES-BMS) |
|---|---|---|---|
| Per patient costs (in €) | |||
| Stent costs | 1,183 (1,136; 1,232) | 600 (577; 623) | 583 (529; 637) |
| Cost of repeat MI | 125 (84; 171) | 90 (55; 128) | 35 (-22; 92) |
| Cost of STT | 56 (28; 87) | 72 (41; 107) | -16 (-61; 29) |
| Cost of revascularization | 318 (227; 428) | 587 (426; 768) | -269 (-474; -75) |
| Cost of repeat CABG | 85 (13; 180) | 322 (167; 499) | -237 (-432; -58) |
| Cost of repeat PCI | 233 (187; 281) | 265 (216; 315) | -32 (-101; 36) |
| Outpatient cardiovascular treatment and drug costs up to year 5 (including anti-platelet therapy) | 1,584 (1,556; 1,612) | 1,567 (1,537; 1,595) | 17 (-23; 57) |
| Total cardiovascular treatment costs over lifetime | 8,123 (7,857; 8,399) | 8,032 (7,725; 8,342) | 91 (-315; 501) |
| Total costs over 5-year follow-up* | 3,160 (3,024; 3,313) | 2,813 (2,634; 3,009) | 347 (108; 585) |
| Total costs over lifetime* | 8,305 (8,069; 8,546) | 7,874 (7,597; 8,161) | 430 (58; 797) |
| Survival (in years) | |||
| Long-term survival | 10.52 (10.25; 10.79) | 10.38 (10.08; 10.67) | 0.14 (-0.26; 0.54) |
| Effectiveness (in QALYs) | |||
| QALYs gained per patient over 5-year follow-up* | 3.05 (3.00; 3.10) | 3.00 (2.95; 3.05) | 0.05 (-0.02; 0.12) |
| QALYs gained per patient over lifetime* | 5.22 (5.11; 5.33) | 5.12 (5.00; 5.24) | 0.10 (-0.06; 0.26) |
| Cost-effectiveness (in € per QALY gained) | |||
| ICER over 5-year follow-up* | 6,890 (-30,745; 44,155) | ||
| ICER over lifetime* | 3,948 (-17,168; 24,580) | ||
EES = everolimus-eluting stent. BMS = bare metal stent. MI = myocardial infarction. STT = stent thrombosis. CABG = coronary artery bypass graft. PCI = percutaneous coronary intervention. QALY = quality-adjusted life years. ICER = incremental cost-effectiveness ratio.
Δ = difference.
* = discounted by 3%.